DE69033653T2 - Plasminogen-aktivator-rezeptor vom urokinasetyp - Google Patents

Plasminogen-aktivator-rezeptor vom urokinasetyp

Info

Publication number
DE69033653T2
DE69033653T2 DE69033653T DE69033653T DE69033653T2 DE 69033653 T2 DE69033653 T2 DE 69033653T2 DE 69033653 T DE69033653 T DE 69033653T DE 69033653 T DE69033653 T DE 69033653T DE 69033653 T2 DE69033653 T2 DE 69033653T2
Authority
DE
Germany
Prior art keywords
preventing
plasminogen activator
type plasminogen
activator receptor
urokinase type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69033653T
Other languages
English (en)
Other versions
DE69033653D1 (de
Inventor
Keld Dano
Francesco Blasi
Louring Roldan
Vittoria Cubellis
Teresa Masucci
Ettore Appella
D Schleuning
Niels Behrendt
Ebbe Ronne
Peter Kristensen
Jari Poellaenen
Eeva-Marjatta Salonen
W Stephens
Hannele Tapiovaara
Antii Vaheri
Birk Moeller
Vincent Ellis
Roge Lund
Michael Ploug
Laszleta Patthy
Charles Pyke
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancerforskningsfondet af 1989
Original Assignee
Cancerforskningsfondet af 1989
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancerforskningsfondet af 1989 filed Critical Cancerforskningsfondet af 1989
Publication of DE69033653D1 publication Critical patent/DE69033653D1/de
Application granted granted Critical
Publication of DE69033653T2 publication Critical patent/DE69033653T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/972—Plasminogen activators
    • G01N2333/9723—Urokinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
DE69033653T 1989-04-07 1990-04-09 Plasminogen-aktivator-rezeptor vom urokinasetyp Expired - Lifetime DE69033653T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33461389A 1989-04-07 1989-04-07
US37485489A 1989-07-03 1989-07-03
PCT/DK1990/000090 WO1990012091A1 (en) 1989-04-07 1990-04-09 Urokinase-type plasminogen activator receptor

Publications (2)

Publication Number Publication Date
DE69033653D1 DE69033653D1 (de) 2000-11-23
DE69033653T2 true DE69033653T2 (de) 2001-06-07

Family

ID=26989284

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69033653T Expired - Lifetime DE69033653T2 (de) 1989-04-07 1990-04-09 Plasminogen-aktivator-rezeptor vom urokinasetyp
DE199090906148T Pending DE467932T1 (de) 1989-04-07 1990-04-09 Plasminogen-aktivator-rezeptor vom urokinasetyp.

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE199090906148T Pending DE467932T1 (de) 1989-04-07 1990-04-09 Plasminogen-aktivator-rezeptor vom urokinasetyp.

Country Status (9)

Country Link
US (1) US6248712B1 (de)
EP (2) EP0467932B1 (de)
JP (2) JPH04506148A (de)
AT (1) ATE197067T1 (de)
AU (2) AU652917B2 (de)
CA (1) CA2051676A1 (de)
DE (2) DE69033653T2 (de)
DK (1) DK0467932T3 (de)
WO (1) WO1990012091A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
CA2094276C (en) * 1990-10-18 2005-08-23 Keld Dano Antibodies against the urokinase receptor and their use
GB9026737D0 (en) * 1990-12-08 1991-01-30 Delta Biotechnology Ltd Cancer treatment
EP0643584B1 (de) * 1992-05-28 2000-03-15 The University Of Toledo Bereitstellung einer für krebszellen cytotoxischen verbindung unter verwendung des weges von plasminogenaktivatormaterial
US5679350A (en) * 1992-05-28 1997-10-21 The University Of Toledo Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
JP2852192B2 (ja) * 1994-07-08 1999-01-27 カンセアフォースクニングスフォンデン・アフ・１９８９（フォンデン・チル・フレメ・アフ・エクスペリメンテル・カンセアフォースクニング） ｕＰＡＲのドメイン２＋３のｕＰＡ結合部位および抗体
IT1271684B (it) * 1994-07-22 1997-06-04 Consiglio Nazionale Ricerche Oligonucleotidi antisenso complementari all'rna messaggero del recettore umano della urochinasi
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
US6277818B1 (en) 1998-10-29 2001-08-21 Angstrom Pharmaceuticals, Inc. Cyclic peptide ligands that target urokinase plasminogen activator receptor
US5994309A (en) 1997-07-25 1999-11-30 Angstrom Pharmaceuticals, Inc. Anti-invasive and anti-angiogenic compositions and methods
AU780730B2 (en) * 1999-10-01 2005-04-14 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
US6896870B1 (en) 1999-10-01 2005-05-24 Angstrom Pharmaceuticals, Inc. Diagnostic probes and therapeutics targeting uPA and uPAR
US6649597B1 (en) 2000-06-22 2003-11-18 The University Of Iowa Research Foundation Targeting vector to the urokinase plasminogen activator receptor
US7045283B2 (en) * 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
ATE361096T1 (de) * 2001-01-25 2007-05-15 San Raffaele Centro Fond Antikörper zur modulierung der upa/upar interaktion und deren verwendungen
KR100871454B1 (ko) 2001-05-21 2008-12-03 옴릭스 바이오파머슈티컬즈 에스. 에이. 단백질 용액으로부터 플라스민(오겐)의 제거
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
EP2390308A1 (de) 2002-02-25 2011-11-30 Vaxiion Therapeutics Inc Minizell-Zusammensetzungen und Verfahren
JP2004137151A (ja) * 2002-10-15 2004-05-13 Keio Gijuku 脳腫瘍の治療・診断薬
EP1691664A4 (de) * 2003-11-18 2008-04-30 Attenuon Llc Antikörper und/oder ihre konjugate, die an das aminoterminale fragment von urokinase binden, zusammensetzungen daraus und ihre verwendungen
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
CA2595935A1 (en) * 2005-01-31 2006-08-03 Fondazione Centro San Raffaele Del Monte Tabor Therapeutic peptides derived from urokinase plasminogen activator receptor
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
EP2071313A4 (de) * 2006-09-28 2012-10-31 Shimadzu Corp Verfahren zur entparaffinisierung von in paraffin eingebetteten präparaten und verfahren zur analyse von in paraffin eingebetteten präparaten
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
PL2117571T3 (pl) * 2006-12-08 2017-08-31 Monopar Therapeutics Inc. Epitop receptora aktywatora plazminogenu typu urokinazy
US8815519B2 (en) * 2006-12-22 2014-08-26 Hvidovre Hospital Method for predicting cancer and other diseases
US8507646B2 (en) * 2007-02-23 2013-08-13 Landing Biotech, Inc. Treating atherosclerosis
CA2681481A1 (en) * 2007-03-16 2008-09-25 Mount Sinai School Of Medicine Induction and/or maintenance of tumor dormancy by disruption of urokinase plasminogen activator receptor-integrin interaction
US9333280B2 (en) 2009-02-25 2016-05-10 Teleflex Medical Incorporated Stabilized enzyme compositions
EP3052051B1 (de) * 2013-09-30 2019-06-12 Teleflex Medical Incorporated Stabilisierte enzymzusammensetzungen
MX2021007843A (es) 2018-12-28 2021-08-11 Vertex Pharma Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso.
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4571421A (en) * 1979-11-05 1986-02-18 Genentech, Inc. Mammalian gene for microbial expression
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
US4791068A (en) * 1984-06-22 1988-12-13 Scripps Clinic And Research Foundation Diagnostic assay for inhibitor of tissue-type and urokinase-type plasminogen activators
JP2757987B2 (ja) * 1985-04-15 1998-05-25 バイオテクノロジー リサーチ パートナーズ，リミテッド ヒト抗‐炎症ホスホリパーゼ阻害蛋白
DK319685A (da) * 1985-07-12 1987-01-13 Fonden Til Fremme Af Eksperime Monoklonale antistoffer, fremgangsmaade til frembringelse af antistofferne, hybridomaceller, der producerer antistofferne, og anvendelse af antistofferne
US5053386A (en) * 1987-07-24 1991-10-01 Tung Ta C Orally administrable anti-metastatic lectin compositions and methods
GB2246779B (en) * 1990-08-03 1994-08-17 Delta Biotechnology Ltd Tumour-associated protease inhibitors targeted to tumour cells
US5340833A (en) * 1992-05-01 1994-08-23 Eisai Co., Ltd. Urokinase inhibitors

Also Published As

Publication number Publication date
JPH04506148A (ja) 1992-10-29
CA2051676A1 (en) 1990-10-08
WO1990012091A1 (en) 1990-10-18
AU652917B2 (en) 1994-09-15
DK0467932T3 (da) 2001-02-12
DE69033653D1 (de) 2000-11-23
EP1013285A3 (de) 2004-05-19
ATE197067T1 (de) 2000-11-15
AU683951B2 (en) 1997-11-27
DE467932T1 (de) 1993-01-14
EP0467932B1 (de) 2000-10-18
AU5528090A (en) 1990-11-05
EP1013285A2 (de) 2000-06-28
JP2002062295A (ja) 2002-02-28
AU8046394A (en) 1995-04-13
EP0467932A1 (de) 1992-01-29
US6248712B1 (en) 2001-06-19

Similar Documents

Publication Publication Date Title
ATE197067T1 (de) Plasminogen-aktivator-rezeptor vom urokinasetyp
SE8000469L (sv) Vevnadsbindmedel och forfarande for dess framstellning samt bindmedlets anvendning
ATE246000T1 (de) Varianten des gewebeplasminogenaktivators mit verbesserter therapeutischer wirkung
MX197183A (es) Activador de plasminogeno de tejido humano
IL52124A (en) Tripeptide derivatives and method for the quantitative determination of plasminogen activators,inhibitors thereof and trypsin,trypsin inhibitors and trypsinogen in human and mammal body fluids and tissue extracts therewith
GB8819607D0 (en) Novel combination
NO173901C (no) Fremgangsmaate, monoklonalt antistoff og sett for maaling av vevplasminogenaktivator-aktivitet
AU633366B2 (en) Human tissue plasminogen activator-human plasminogen activator inhibitor complex immunoassay and kit therefor
NO168055C (no) Fremgangsmaate for fremstilling av human vevplasminogenaktivator og urokinase-type plasminogenaktivator.
DK166489D0 (da) Monoklonale antistoffer mod vaevsplasminogen-aktivator (t-pa), deres fremstilling og anvendelse
DK112290A (da) Vaevsplasminogenaktivator-variant
DE69000290D1 (de) Thrombotische zusammensetzungen.
ATE64532T1 (de) Pharmazeutische zusammensetzung mit thrombolytischer wirkung.
DK7491D0 (da) Vaevsplasminogenaktivatoranalog
BR1100888A (pt) Variantes de ativador de plasminogênios de tecido, composições e métodos de uso da mesma
DK96888A (da) Rekombinant humant vaevsplasminogen aktivatormateriale
IE882534L (en) Peg complex of tissue plasminogen activator
IL109760A0 (en) Modified human tissue-type plasminogen activator which retains its biological activity and is characterized by an increased in vivo hlaf-life
ATE100330T1 (de) Plasminogenaktivator und thrombolytischer wirkstoff.
GB8826692D0 (en) Tissue plasminogen activator
NO880831D0 (no) Rekombinant human vevsplasminogen-aktivatorblanding.
GB9000629D0 (en) Tissue plasminogen activator
IE883342L (en) Human tissue-type plasminogen activator variant
IL109735A0 (en) Tissue plasminogen activator having zymonogenic or fibrin specific properties
IL92015A0 (en) Tissue plasminogen activator muteins and processes for the preparation thereof